Antimicrobial resistance in clinical Escherichia coli isolated from companion animals in Australia was written by Saputra, Sugiyono;Jordan, David;Mitchell, Tahlia;Wong, Hui San;Abraham, Rebecca J.;Kidsley, Amanda;Turnidge, John;Trott, Darren J.;Abraham, Sam. And the article was included in Veterinary Microbiology in 2017.Product Details of 113617-63-3 This article mentions the following:
Multidrug-resistant (MDR) Escherichia coli have become a major public health concern to both humans and animal health. While the frequency of antimicrobial resistance (AMR) in clin. E. coli is monitored regularly in human medicine, current frequency of AMR in companion animals remains unknown in Australia. In this study we conducted antimicrobial susceptibility testing (AST) and where possible, determined potential risk factors for MDR infection among 883 clin. Escherichia coli isolated from dogs (n = 514), cats (n = 341) and horses (n = 28). AST was undertaken for 15 antimicrobial agents according to the Clin. Laboratory Standards Institute (CLSI) guidelines and interpreted using epidemiol. cut-off values (ECOFFs) as well as CLSI veterinary and human clin. breakpoints. The AST revealed complete absence of resistance to carbapenems while resistance to amikacin was observed at a low level in isolates from dogs (1.6%) and cats (1.5%) compared to horses (10.7%). Among dog isolates, resistance to fluoroquinolones ranged from 9.1%-9.3% whereas among cat isolates, it ranged from 3.2%-5%. Among dog isolates, the proportion showing a 3rd generation cephalosporin (3GC) non-wild type phenotype was significantly higher (P < 0.05) in skin and soft tissue infection (SSTI, n = 122) isolates (17.2%-20.5%) compared to urinary tract infection (UTI, n = 392) isolates (9.9%-10.2%). The frequency of multidrug resistance was 18.1%, 11.7% and 42.9% in dog, cat and horse isolates, resp. Risk factor anal. revealed that MDR E. coli isolated from UTI were pos. associated with chronicity of infection and previous antimicrobial treatment. Dogs and cats with chronic UTI that had been previously treated with antimicrobials were eight times and six times more likely to be infected with MDR E. coli compared to dogs and cats with non-chronic UTI, and no history of antimicrobial treatment, resp. This study revealed that pre-existing disease condition and prior antimicrobial use were the major risks associated with UTI with MDR E. coli in companion animals. In the experiment, the researchers used many compounds, for example, 1-Cyclopropyl-7-(cis-3,5-dimethylpiperazin-1-yl)-5,6,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (cas: 113617-63-3Product Details of 113617-63-3).
1-Cyclopropyl-7-(cis-3,5-dimethylpiperazin-1-yl)-5,6,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (cas: 113617-63-3) belongs to piperazine derivatives. Piperazine belongs to the family of medicines called anthelmintics. Outside the body, piperazine has a remarkable power to dissolve uric acid and producing a soluble urate, but in clinical experience it has not proved equally successful. Product Details of 113617-63-3
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics